✦ LIBER ✦

The use of predicting factors and surrogate markers in breast cancer biopsies treated with targeted erbB tyrosine kinase inhibitor

Book ID: 117659522
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 274 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80830-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib: A small-molecule inhibitor of

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

✍ Amye J. Tevaarwerk; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 188 KB

A Multicenter Phase II Trial of ZD6474,

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

✍ Dickler, M.N. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Usefulness of monitoring the circulating

Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

✍ Nobuhisa Ishikawa; Noboru Hattori; Akihoto Yokoyama; Sonosuke Tanaka; Ryohei Nis 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 289 KB 👁 2 views

## Abstract Krebs von den Lungen‐6 (KL‐6) is a high molecular weight glycoprotein classified in the category of human MUC1 mucin. KL‐6 has been reported to serve as a sensitive marker for interstitial pneumonia; however, recent studies have suggested that it can also be used as a tumor marker as it